Gilead signs antibody agreement with Biocytogen amid growing ADC excitement

CAR-T Digest - August 2020

19 Feb 2024: Gilead signs antibody agreement with Biocytogen amid growing ADC excitement

Biocytogen Pharmaceuticals announces a new antibody evaluation and option agreement with Gilead Sciences, providing access to its fully human antibody library
Under the deal, Gilead has a three-year nomination period to select targets and evaluate antibodies, with the option to acquire selected antibodies for global therapeutic development
Biocytogen’s expertise includes four genetically engineered RenMice platforms for discovering various antibody types, including bispecific antibody-drug conjugates (ADCs) and TCR-mimic antibodies
The company has been involved in numerous therapeutic antibody and clinical asset co-development agreements, with over 50 partnerships as of June 2023
Recent collaborations with Radiance Biopharma, Ona Therapeutics, and Myricx Bio highlight Biocytogen’s focus on advancing ADC expertise through strategic partnerships
This partnership aligns with a trend of significant deals in the ADC sector, exemplified by Amgen’s $2 billion licensing agreement with Synaffix in January 2023, indicating growing interest and investment in ADC technology